Sex and gender differences in cancer pathogenesis and pharmacology
Open accessThe DOI matches its Crossref record; 92 of the 94 references it cites were found in a registry or an index.
Abstract
Sex and gender may influence the epidemiology, pathogenesis, and prognosis of cancer. This narrative review describes sex and gender differences in the epidemiology and pathogenesis of cancer, and how such differences may impact the pharmacodynamics and pharmacokinetics of cancer treatment. For most types of cancer unrelated to reproductive function, incidence is higher in males than in females, except for gallbladder and thyroid cancers, which are much more common in women. Cancer mortality is higher in men than women; women account for a larger proportion of survivors. These differences may be related to biological differences in pathogenesis or differences in behaviors relating to cancer risk or detection. The pharmacokinetics and pharmacodynamics of cancer therapies also differ between sexes due to differences in body composition, physiology, and receptor expression. Overall, sex and gender are essential variables to be considered in research and clinical practice, influencing diagnosis, subtyping (biomarkers), prognostication, treatment, and dosage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Proportion of males and females among new diagnoses of selected non-reproductive cancers (left) and among those living with selected non-reproductive cancers over 5 years (right) according to GLOBOCAN 2022 data [9, 10]. CNS central nervous system](https://figures.cochat.ai/paper-figures/2c22768a6ef34a10bcbfc18f71bce890/sex-and-gender-differences-in-cancer-pathogenesis-and-pharmacology-figure-1.jpg)
![Fig. 2 Differential effects of sex hormones on immune cells [40]. Ig immunoglobulin, IL interleukin. Figure adapted from Irelli A, et al. Biomedicines 2020;8(7):232 (https://doi.org/10.3390/biomedicines8070232), under the terms and conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) license (http://creativecommons.org/licenses/by/4.0/). Adaptations from the original figure include a simpler presentation of key concepts and a shorter figure legend](https://figures.cochat.ai/paper-figures/e8239151e1c3401b8b8505559980662f/sex-and-gender-differences-in-cancer-pathogenesis-and-pharmacology-figure-2.jpg)
![Fig. 3 Metabolic differences between male and female cancer cells [27]. *Prior to menopause. CRC colorectal cancer, GLUT1 uniporter glucose transporter 1, MCT monocarboxylic acid transporter, NADPH nicotinamide adenine dinucleotide phosphate, NSCLC non-small cell lung cancer, PP pentose phosphate, TCA tricarboxylic acid](https://figures.cochat.ai/paper-figures/f18da77246164caf9976b8d85218e14e/sex-and-gender-differences-in-cancer-pathogenesis-and-pharmacology-figure-3.jpg)
![Fig. 4 Sex-related anatomical and physiological differences that affect drug pharmacokinetics and generally result in higher systemic exposure in females than in males [2, 75]. *Affected by body mass index. AUC area under the concentration–time curve, Cmax maximal plasma concentration, CYP450 cytochrome P450, GI gastrointestinal, tmax time to maximal plasma concentration](https://figures.cochat.ai/paper-figures/d5d65d54e6c34df0a81e88255ea29b71/sex-and-gender-differences-in-cancer-pathogenesis-and-pharmacology-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sex differences in pharmacokinetics and plasticity trajectories remain largely unmapped, despite evidence that network biomarkers and treatment prediction are sensitive to demographic and biological heterogeneity [93,232,233,234].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [234]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“In male cancer cells, the glycolytic pathway preferentially produces lactate via the Warburg effect [69], whereas this is less marked in female cells, which often metabolize glucose via the less energy-efficient pentose phosphate pathway [27].”
Thompson, A. E., Anisimowicz, Y., Miedema, B., Hogg, W., Wodchis, W. P., & Aubrey-Bassler, K. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0440-0 · Cited by 1,148
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940 · cited 1×
“Increased lactate production can promote p16 INK4α [61] Non-small cell lung cancer CDH13 [58], GATA5 [58], KCNH5 [52], KCNH8 [52], PAX6 [58], RARB [52] ERα [55], MGMT [63], RASSF1 [60] epithelial–mesenchymal transition, angiogenesis, and immune evasion [70].”
Sex differences in pharmacokinetics predict adverse drug reactions in women
Zucker, I., & Prendergast, B. J. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00308-5 · Cited by 777
Sex and gender differences in health: Science & Society Series on Sex and Science
Regitz‐Zagrosek, V. (2012) · The EMBO Reports · doi:10.1038/embor.2012.87 · Cited by 572
Gender, psychosocial factors and the use of medical services: a longitudinal analysis
Green, C. A., & Pope, C. R. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00440-7 · Cited by 469
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias
Dunford, A., Weinstock, D. M., Savova, V., Schumacher, S. E., Cleary, J. P., Yoda, A., Sullivan, T. J., Hess, J. M., Gimelbrant, A. A., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3726 · Cited by 453
Clocchiatti, A., Cora, E., Zhang, Y., & Dotto, G. P. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.30 · Cited by 374
Sex Differences in Drug Disposition
Soldin, O. P., Chung, S. H., & Mattison, D. R. (2011) · BioMed Research International · doi:10.1155/2011/187103 · Cited by 341
Cited by
Sex-related differences in the efficacy and toxicity of cancer treatments
Santaballa, A., Rodríguez, J. A. M., Cardeña-Gutiérrez, A., Callejo, V. M., Higuera, O., Bernárdez, B., Moreno, E., & Majem, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03893-2 · Cited by 20
Self-citationJi, Y., Yan, S., Xu, W., Yang, M., Chen, A., Hou, S., & Du, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01971k · Cited by 8
Zhang, H., Xue, R., Kong, X., Zhao, M., & Jin, Z. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1615378 · Cited by 7
Cui, Y., Bao, X., Liu, D., Mu, H., & Yu, G. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.109245 · Cited by 5
Erices, J. I., González, E., Salgado, M., Ponce, C. B., Freire, M., Sepúlveda-Hermosilla, G., Ampuero, D., Blanco, A., Gárate‐Calderón, V., Pablo Báez, B., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1658528 · Cited by 4
Metadata
- Authors
- Bernardez, B., Higuera, O., Martinez-Callejo, V., Cardeña-Gutiérrez, A., Marcos Rodríguez, J. A., Santaballa Bertrán, A., Majem, M., & Moreno-Martínez, M.-E.
- Affiliations
- Hospital Universitario La Paz (ES)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital de Sant Pau (ES)
- Corresponding author
- Cardeña-Gutiérrez, Ana
- ORCID
- Venue
- Clinical and Translational Oncology
- Published
- 2025-04-01
- Volume
- 27
- Issue
- 10
- Pages
- 3837-3848
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- PMC
- PMC12460385
- OpenAlex
- W4409086376
- Cited by
- 27
- References
- 94
- Citations by year
- 2026: 21 · 2025: 6
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Clinical & Translational Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Hispana (submittedVersion, cc-by)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- Funders
- Organon
- Sociedad Española de Oncología Médica
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- sex differences, gender differences, cancer epidemiology, carcinogenesis, pharmacodynamics, cancer mortality, cancer incidence, body composition, receptor expression, tumor markers, cancer prognosis, dosage
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasms, Prognosis, Sex Characteristics, Sex Factors, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex and gender differences in cancer pathogenesis and pharmacology. https://app.cochat.ai/papers/10.1007/s12094-025-03894-1
- The paper
- Bernardez, B., Higuera, O., Martinez-Callejo, V., Cardeña-Gutiérrez, A., Marcos Rodríguez, J. A., Santaballa Bertrán, A., Majem, M., & Moreno-Martínez, M.-E. (2025). Sex and gender differences in cancer pathogenesis and pharmacology. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-03894-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.